Latikafusp represents a distinct therapeutic strategy for managing specific cancers, particularly those involving fusion anaplastic lymphoma kinase molecules. This drug functions as an inhibitor of altered ALK proteins, demonstrating potential in preclinical studies and phase clinical studies. Its mode of effect offers a precise means to disrupt… Read More